Biogen Inc (BIIB)
Quick ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | US$ in thousands | 2,375,000 | 1,699,200 | 1,908,900 | 1,074,400 | 1,049,900 | 2,287,900 | 2,617,800 | 2,898,200 | 3,419,300 | 3,675,600 | 2,646,600 | 1,749,300 | 2,261,400 | 1,541,800 | 1,742,000 | 1,217,500 | 1,331,200 | 2,224,800 | 2,384,900 | 2,591,300 |
Short-term investments | US$ in thousands | 179,700 | 304,700 | 302,700 | 329,500 | 416,800 | 413,600 | 4,177,500 | 2,821,200 | 2,264,600 | 2,131,500 | 2,936,900 | 2,862,700 | 2,589,600 | 2,579,500 | 1,308,800 | 1,320,000 | 1,278,900 | 1,355,000 | 1,942,700 | 1,269,100 |
Receivables | US$ in thousands | 1,404,800 | -2,400 | -2,400 | -2,400 | 1,664,100 | — | — | 1,634,400 | 1,705,000 | 1,568,800 | 1,567,600 | 1,632,000 | 1,549,400 | 1,723,000 | 1,688,000 | 1,854,300 | 1,913,800 | 2,024,900 | 2,133,600 | 2,092,600 |
Total current liabilities | US$ in thousands | 5,528,800 | 5,425,000 | 3,108,200 | 3,222,800 | 3,434,300 | 5,022,300 | 3,186,500 | 3,014,900 | 3,272,800 | 3,926,400 | 5,018,000 | 3,946,600 | 4,298,200 | 4,211,600 | 3,347,200 | 3,165,800 | 3,742,200 | 3,804,000 | 3,447,100 | 4,638,600 |
Quick ratio | 0.72 | 0.37 | 0.71 | 0.43 | 0.91 | 0.54 | 2.13 | 2.44 | 2.26 | 1.88 | 1.43 | 1.58 | 1.49 | 1.39 | 1.42 | 1.39 | 1.21 | 1.47 | 1.87 | 1.28 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,375,000K
+ $179,700K
+ $1,404,800K)
÷ $5,528,800K
= 0.72
The quick ratio of Biogen Inc has experienced fluctuations over the past few years. It started at a healthy level of 1.28 as of March 31, 2020, indicating that the company had enough liquid assets to cover its current liabilities.
The ratio improved significantly to 2.26 by December 31, 2022, and continued to increase to 2.44 by March 31, 2023, showing a strong ability to meet short-term obligations.
However, there was a sharp decline in the quick ratio to 0.37 by September 30, 2024, signaling a potential liquidity issue as the company may struggle to meet its short-term liabilities with its current liquid assets.
Overall, while the quick ratio of Biogen Inc has shown some volatility, it is important for the company to closely monitor its liquidity position to ensure it can meet its short-term obligations effectively.
Peer comparison
Dec 31, 2024